AI News NQ Analysis

FRONTEO and Keio University School of Medicine Acquire Two Patents for Conversational AI Program Supporting Depression Diagnosis

NQ Score 100/100

AI Summary (NQ-processed)

FRONTEO Inc. and Keio University School of Medicine have jointly developed and patented two conversational AI programs designed to assist in the diagnosis of depression. These programs analyze approximately 10 minutes of free conversation between patients and healthcare professionals to provide objective diagnostic support, aiming to improve early detection and treatment access for depression patients.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the name of the company that partnered with Keio University School of Medicine to develop the AI program?
A: FRONTEO Inc. partnered with Keio University School of Medicine to develop the conversational AI programs.
Q: How many patents did FRONTEO and Keio University School of Medicine acquire for their AI programs?
A: FRONTEO and Keio University School of Medicine acquired two patents for their conversational AI programs.
Q: What mental health condition do the AI programs developed by FRONTEO aim to assist in diagnosing?
A: The AI programs developed by FRONTEO aim to assist in diagnosing depression.
Q: Approximately how long is the patient conversation analyzed by the FRONTEO AI program?
A: The FRONTEO AI program analyzes approximately 10 minutes of free conversation between patients and professionals.
Q: Which institution collaborated with FRONTEO to create the depression diagnosis support AI?
A: Keio University School of Medicine collaborated with FRONTEO to create the depression diagnosis support AI.